BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 9 2024 06:00:46 提供 Nasdaq GlobeNewswire

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

03 9 2024 09:02:32 提供 NetDania Notify

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

29 8 2024 09:17:26 提供 NetDania Notify

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

28 8 2024 08:45:07 提供 NetDania Notify

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

26 8 2024 08:45:03 提供 NetDania Notify

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

23 8 2024 09:45:41 提供 NetDania Notify

BioCryst to Present at Upcoming Investor Conferences

22 8 2024 06:00:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

09 8 2024 08:45:50 提供 NetDania Notify

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

07 8 2024 08:45:08 提供 NetDania Notify

BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update

05 8 2024 06:00:24 提供 Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 8 2024 06:00:47 提供 Nasdaq GlobeNewswire

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

29 7 2024 08:56:40 提供 NetDania Notify

BioCryst to Report Second Quarter 2024 Financial Results on August 5

22 7 2024 06:00:09 提供 Nasdaq GlobeNewswire

ORLADEYO® (berotralstat) Approved in Peru

09 7 2024 06:00:00 提供 Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 7 2024 06:00:06 提供 Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 6 2024 06:00:59 提供 Nasdaq GlobeNewswire

BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment

02 6 2024 03:00:13 提供 Nasdaq GlobeNewswire

BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology

14 5 2024 06:00:53 提供 Nasdaq GlobeNewswire

ORLADEYO® (berotralstat) Approved in Mexico

13 5 2024 06:00:00 提供 Nasdaq GlobeNewswire

BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat)

09 5 2024 06:00:00 提供 Nasdaq GlobeNewswire